A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the anti-tumor activity of single-agent Edotecarin by determining the objective response rate
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
EDOABC-4439-001
NCT00067314
June 2003
June 2007
Name | Location |
---|---|
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |